Pursuant to the provisions of Regulation 34 of the SEBI (LODR) Regulations, 2015 we are enclosing herewith Annual Report for the Financial Year 2024-25 along with the Notice of 32nd Annual ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs & Industries Ltd has submitted its 32nd Annual Report for FY 2024-25 to BSE under Regulation 34 of SEBI (LODR) Regulations, 2015. The 32nd Annual General Meeting is scheduled for Monday, 29th September 2025 at 11:30 AM at Hotel Krsna Lila, Sanand, Gujarat. Shareholders will vote on ordinary business items including adoption of FY25 audited financials, re-appointment of Mrs. Abha Agrawal (promoter, holding 8.39% stake) as Director retiring by rotation, and re-appointment of M/s Jaymin Shah & Associates as Statutory Auditors for one year. Special business includes re-appointment of Mr. Arvind Sapkal as Independent Director for a second 5-year term (Oct 2025 to Sep 2030) and appointment of M/s Meenu Maheshwari & Associates as Secretarial Auditor for 5 years (FY 2025-26 to FY 2029-30). The company is also seeking shareholder approval for material related party transactions with Ishita Pharmaceuticals and Anvi Lifesciences Private Limited, where Managing Director Jagdish Agrawal and CFO Sumit Agrawal have partnership interests, as these transactions may exceed 10% of annual turnover.
Retail shareholders should review the upcoming AGM resolutions carefully, particularly the material related party transactions with promoter-linked entities (Ishita Pharmaceuticals and Anvi Lifesciences) which could exceed 10% of turnover. Voting cutoff date is 22nd September 2025, and the e-voting window runs from 26-28 September 2025.